Hydroxysafflor Yellow A improves diabetic nephropathy by inhibiting PI3K/AKT/mTOR pathway based on a multidimensional study

Back to news list

Source: Frontiers Medicine

Original: https://www.frontiersin.org/articles/10.3389/fmed.2026.1747346...

Published: 2026-02-02T00:00:00Z

Hydroxysafflor Yellow A (HSYA) is a safflower compound that has been studied as a potential treatment for diabetic nephropathy – kidney damage caused by diabetes.[7] The research team used computational methods to identify 236 possible targets that HSYA acts on in the body, finding the proteins AKT1, PI3K and mTOR to be the most important.[7] Analyzes have shown that HSYA affects signaling pathways associated with autophagy (the process by which cells clear away their harmful parts) and other pathways relevant to kidney damage.[7] In experiments on diabetic mice, HSYA reduced kidney fibrosis (scar tissue formation) and altered the expression of autophagy-related genes.[7] The results suggest that HSYA could alleviate diabetic nephropathy by improving fibrosis and modulating autophagy.[7] The study provides a theoretical basis for the further development of HSYA as a potential therapeutic agent, although this is still preliminary evidence from experimental studies.